Pancreatic Cancer Research

ResearcherNational Medical Products AdministrationActive in the last 2 years

Yixuan Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2588-1663; OpenAlex author ID A5069618108. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. A pH-responsive liposomal nanoplatform for reprogramming lactate metabolism and immunogenic activation in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2026.124401↗
  2. SKIL Promotes Pancreatic Cancer Metastasis by Inhibiting TSPYL2 to Activate the TGF-β Pathway. Co-author DOI 10.1002/cai2.70011↗
  3. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202305279↗
  4. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Co-author DOI 10.1038/s41388-022-02328-4↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ying Lv · 3 shared papers, 2022–2026 · strength 0.54
  2. Xiaoping Zou · 3 shared papers, 2022–2026 · strength 0.54
  3. Shu Zhang · 2 shared papers, 2022–2024 · strength 0.31
  4. Xiaobing Wang · 1 shared paper, 2025 · strength 0.28
  5. Chenxi Wang · 1 shared paper, 2025 · strength 0.28
  6. Yin Zhang · 1 shared paper, 2026 · strength 0.24
  7. Jiajun Zhang · 1 shared paper, 2026 · strength 0.24
  8. Yu Zhao · 1 shared paper, 2026 · strength 0.24
  9. Shijin Xu · 1 shared paper, 2024 · strength 0.18
  10. Zhang Yin · 1 shared paper, 2024 · strength 0.18
  11. Lei Wang · 1 shared paper, 2022 · strength 0.13
  12. Hao Wu · 1 shared paper, 2022 · strength 0.13
  13. Chao Yan · 1 shared paper, 2022 · strength 0.13
  14. Shanshan Shen · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.